We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

QIAGEN

Qiagen is a provider of sample and assay technologies for molecular diagnostics and applied testing, including comple... read more Featured Products: More products

Download Mobile App




Paper-Based Dengue NS1 Rapid Diagnostic Test Validated

By LabMedica International staff writers
Posted on 06 Aug 2021
Print article
Schematic representation of the procedure for dengue NS1 detection by using DEN-NS1-PAD (Photo courtesy of King Mongkut’s University of Technology Thonburi)
Schematic representation of the procedure for dengue NS1 detection by using DEN-NS1-PAD (Photo courtesy of King Mongkut’s University of Technology Thonburi)
Dengue virus (DENV) infection is one of the world’s most important neglected tropical diseases and the fastest spreading mosquito-borne disease. About 70% of the 3.9 billion people at risk live in Asian Pacific countries, mainly in Southeast Asia.

The early diagnosis of dengue is essential for clinical assessment, investigations, and disease control. Although, molecular assays were used as the gold standard for diagnosing dengue infection, these methods are expensive, tedious, and need the expertise of technicians, which is unsuitable for point-of-care tests in remote areas.

A multi-disciplinary team of scientists working with those at King Mongkut’s University of Technology Thonburi (Bangkok, Thailand) analyzed 250 dengue-suspected sera samples used in a study were the archived sera of dengue-suspected patients, routinely collected during the peak of the disease epidemic in Thailand, from July to September 2019. Patients’ blood samples were routinely tested by a commercial dengue NS1 test kit (Dengue Duo test, SD BIOLINE, Abbott Park, IL, USA), immediately after collection to diagnose and treat patients.

The team developed a simple diagnostic kit for dengue NS1 testing based on a wax-printed microfluidic paper-based analytical device (μPAD), so-called DEN-NS1-PAD for sensitive and specific detection of dengue NS1. The DEN-NS1-PAD allows specific interaction between reporter antibodies (rAb) labeled with Gold Nanoparticles (AuNPs) and dengue NS1 protein. Viral RNAs in serum samples were extracted by using QIAamp Viral RNA Mini Kit (QIAGEN, Hilden, Germany). They were then subjected to RT-PCR using dengue-specific primers, and the RT-PCR products were used as templates for the nested-PCR reaction.

The team reported that out of the 250 dengue-suspected patients who were admitted to the hospital over the study period, there were two commercialized RDT tested, of which 219 were from SD BIOLINE Dengue Duo test and PCR testing. Prevalence of dengue infection was 45.21% by SD-NS1, 47.49% by DEN-NS1-PAD and 45.21% by nested-PCR. The results from the nested-PCR were 99 of dengue positive and 120 negative. The limit of detection of DEN-NS1-PAD was 0.78 ng/mL. It showed 88.89% sensitivity, 86.67% specificity, and a substantial agreement correlation compared with nested-PCR. In contrast, SD BIOLINE for NS1 (SD-NS1) detection showed 87.88% sensitivity, 90.00% specificity, and also had a substantial agreement correlation with nested-PCR.

The authors concluded that the performance of the DEN-NS1-PAD to be almost on par with SD-NS1 in detecting dengue infection in acute febrile cases. The device possesses better sensitivity than SD-NS1, especially for the diagnosed patient after day five of illness. The DEN-NS1-PAD can be a potential alternative to existing commercial RDTs in the detection of acute dengue infection in the future. The study was originally published in the June 2021 issue of the International Journal of Infectious Diseases.

Related Links:

King Mongkut’s University of Technology Thonburi
SD BIOLINE
QIAGEN


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.